Johann Poetzl

Multiple switches between <scp>GP</scp>2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory <scp>EGALITY</scp> study

Sascha Gerdes, Diamant Thaçi, C.E.M. Griffiths et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 74 citations · Full text

2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)

Bart Corsaro, Tong‐Yuan Yang, Rocio Murphy et al. · Bioanalysis · 2021 · 60 citations

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study

Marco Matucci‐Cerinic, Yannick Allanore, Arthur Kavanaugh et al. · RMD Open · 2018 · 40 citations · Full text

GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods

Oliver von Richter, Lena Lemke, Halimu N. Haliduola et al. · Expert Opinion on Biological Therapy · 2019 · 36 citations · Full text

GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes

Oliver von Richter, Andrej Skerjanec, Miguel Afonso Filipe et al. · British Journal of Clinical Pharmacology · 2016 · 33 citations · Full text